April 17, 2007 - Boston Scientific announced today, the FDA approval of its ACUITY Steerable left ventricular lead, for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
The ACUITY Steerable lead, available in July, provides physicians with four configurations for stimulating the left side of the heart. This allows physicians to change the stimulation site non-invasively after implant, which helps avoid the need for an additional surgical procedure.
A lead is an insulated wire that carries the heart signal to the implanted device and delivers energy from the device to the heart. In most cases, leads are passed into the heart through veins.